Publications

  1. Foran JM. Do cytogenetics affect the post-remission strategy for older patients with AML in CR1? Best Pract Res Clin Haematol. 2017 Dec; 30 (4):306-311 Epub 2017 Oct 07
    View PubMed
  2. Altman JK, Foran JM, Pratz KW, Trone D, Cortes JE, Tallman MS. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2017 Nov 15 [Epub ahead of print]
    View PubMed
  3. Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Battiwalla M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D'Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hashmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzieri D, Savani BN, Schouten HC, Sabloff M, Seftel M, Seo S, Sorror ML, Szer J, Wirk BM, Wood WA, Artz A. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017 Aug 31; 130 (9):1156-1164 Epub 2017 July 03
    View PubMed
  4. Ertz-Archambault N, Kosiorek H, Taylor GE, Kelemen K, Dueck A, Castro J, Marino R, Gauthier S, Finn L, Sproat LZ, Palmer J, Mesa RA, Al-Kali A, Foran J, Tibes R. Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. JAMA Oncol. 2017 Jul 1; 3 (7):936-943
    View PubMed
  5. O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Gore SD, Hall AC, Kropf P, Lancet J, Maness LJ, Marcucci G, Martin MG, Moore JO, Olin R, Peker D, Pollyea DA, Pratz K, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wang ES, Wieduwilt M, Gregory K, Ogba N. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Jul; 15 (7):926-957
    View PubMed
  6. Knorr KL, Finn LE, Smith BD, Hess AD, Foran JM, Karp JE, Kaufmann SH. Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo. Stem Cells Transl Med. 2017 Mar; 6 (3):840-850 Epub 2016 Nov 07
    View PubMed
  7. Colon-Otero G, Van Wier SA, Ahmann GJ, Braggio E, Albertie ML, Weis JA, Ailawadhi S, Cerhan JR, Vishnu P, Jorgensen MS, Foran JM, Thomas CS, Fonseca R. Prevalence of BCL-2J(H) Translocation in Healthy African Americans. Ann Hematol. 2017 Jan; 96: (1)51-55.
    View PubMed
  8. Knorr KL, Finn LE, Smith BD, Hess AD, Foran JM, Karp JE, Kaufmann SH. Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells From Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo. Stem Cells Transl Med. 2016 Nov 07;
    View PubMed
  9. Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, Barnett E, Marine J, Miranda M, Azaryan A, Yu X, Nava-Parada P, Mei J, Kipps TJ. Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. Haematologica 2016 Jul; 101 (7):e295-8 Epub 2016 May 05
    View PubMed
  10. Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox DS, Wissel P, Kantarjian H. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016 Jun 15; 122 (12):1871-9 Epub 2016 Mar 18
    View PubMed
  11. Finn LE, Foran JM. Are we curing more older adults with acute myeloid leukemia with allogeneic transplantation in CR1? Curr Opin Hematol. 2016 Mar; 23: (2)95-101.
    View PubMed
  12. Ailawadhi S, Advani P, Yang D, Ghosh R, Swaika A, Roy V, Foran J, Colon-Otero G, Chanan-Khan A. Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis. Cancer. 2016 Feb 15; 122: (4)618-25.
    View PubMed
  13. Finn L, Sproat L, Heckman MG, Jiang L, Diehl NN, Ketterling R, Tibes R, Valdez R, Foran J. Epidemiology of adult acute myeloid leukemia: Impact of exposures on clinical phenotypes and outcomes after therapy. Cancer Epidemiol. 2015 Dec; 39: (6)1084-92.
    View PubMed
  14. Tibes R, Al-Kali A, Oliver GR, Delman DH, Hansen N, Bhagavatula K, Mohan J, Rakhshan F, Wood T, Foran JM, Mesa RA, Bogenberger JM. The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia. J Hematol Oncol. 2015 Oct 20; 8:114.
    View PubMed
  15. Crozier JA, Sher T, Yang D, Swaika A, Foran J, Ghosh R, Tun H, Colon-Otero G, Kelly K, Chanan-Khan A, Ailawadhi S. Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database Review. Clin Lymphoma Myeloma Leuk. 2015 Oct; 15: (10)578-85.
    View PubMed
  16. Advani P, Paulus A, Murray P, Jiang L, Goff R, Pooley R, Jain M, Garner H, Foran J. A rare case of primary high-grade large B-cell lymphoma of the sciatic nerve. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15: (6)e117-20.
    View PubMed
  17. Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol. 2015 Jan 20; 33: (3)251-7.
    View PubMed
  18. Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, Bracci PM, de Sanjose S, Smedby KE, Chiu BC, Zhang Y, Mbulaiteye SM, Monnereau A, Turner JJ, Clavel J, Adami HO, Chang ET, Glimelius B, Hjalgrim H, Melbye M, Crosignani P, di Lollo S, Miligi L, Nanni O, Ramazzotti V, Rodella S, Costantini AS, Stagnaro E, Tumino R, Vindigni C, Vineis P, Becker N, Benavente Y, Boffetta P, Brennan P, Cocco P, Foretova L, Maynadie M, Nieters A, Staines A, Colt JS, Cozen W, Davis S, de Roos AJ, Hartge P, Rothman N, Severson RK, Holly EA, Call TG, Feldman AL, Habermann TM, Liebow M, Blair A, Cantor KP, Kane EV, Lightfoot T, Roman E, Smith A, Brooks-Wilson A, Connors JM, Gascoyne RD, Spinelli JJ, Armstrong BK, Kricker A, Holford TR, Lan Q, Zheng T, Orsi L, Dal Maso L, Franceschi S, La Vecchia C, Negri E, Serraino D, Bernstein L, Levine A, Friedberg JW, Kelly JL, Berndt SI, Birmann BM, Clarke CA, Flowers CR, Foran JM, Kadin ME, Paltiel O, Weisenburger DD, Linet MS, Sampson JN. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014 Aug; 2014: (48)130-44.
    View PubMed
  19. Cerhan JR, Kricker A, Paltiel O, Flowers CR, Wang SS, Monnereau A, Blair A, Dal Maso L, Kane EV, Nieters A, Foran JM, Miligi L, Clavel J, Bernstein L, Rothman N, Slager SL, Sampson JN, Morton LM, Skibola CF. Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014 Aug; 2014: (48)15-25.
    View PubMed
  20. Tao L, Foran JM, Clarke CA, Gomez SL, Keegan TH. Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era. Blood. 2014 Jun 05; 123 (23):3553-62 Epub 2014 Apr 04
    View PubMed
  21. Foran JM. Frontline therapy of AML: should the older patient be treated differently? Curr Hematol Malig Rep. 2014 Jun; 9 (2):100-8
    View PubMed
  22. Paulus A, Masood A, Miller KC, Khan AN, Akhtar D, Advani P, Foran J, Rivera C, Roy V, Colon-Otero G, Chitta K, Chanan-Khan A. The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs. Br J Haematol. 2014 Apr; 165: (1)78-88.
    View PubMed
  23. Paulus A, Chitta K, Akhtar S, Personett D, Miller KC, Thompson KJ, Carr J, Kumar S, Roy V, Ansell SM, Mikhael JR, Dispenzieri A, Reeder CB, Rivera CE, Foran J, Chanan-Khan A. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenstrom macroglobulinaemia. Br J Haematol. 2014 Feb; 164: (3)352-365.
    View PubMed
  24. Foran JM, Pavletic SZ, Logan BR, Agovi-Johnson MA, Perez WS, Bolwell BJ, Bornhauser M, Bredeson CN, Cairo MS, Camitta BM, Copelan EA, Dehn J, Gale RP, George B, Gupta V, Hale GA, Lazarus HM, Litzow MR, Maharaj D, Marks DI, Martino R, Maziarz RT, Rowe JM, Rowlings PA, Savani BN, Savoie ML, Szer J, Waller EK, Wiernik PH, Weisdorf DJ. Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research. Biol Blood Marrow Transplant. 2013 Jul; 19: (7)1102-8.
    View PubMed
  25. Keegan TH, Moy LM, Foran JM, Alizadeh AA, Chang ET, Shema SJ, Schupp CW, Clarke CA, Glaser SL. Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study. Leuk Lymphoma. 2013 Apr; 54(4):743-51. Epub 2012 Sep 28.
    View PubMed
  26. Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, Rohatiner A, Advani A, Foran J, Hess G, Coiffier B, Czuczman M, Gine E, Durrant S, Kneissl M, Luu KT, Hua SY, Boni J, Vandendries E, Dang NH. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013 Feb 10; 31(5):573-83. Epub 2013 Jan 07.
    View PubMed
  27. Flowers CR, Shenoy PJ, Borate U, Bumpers K, Douglas-Holland T, King N, Brawley OW, Lipscomb J, Lechowicz MJ, Sinha R, Grover RS, Bernal-Mizrachi L, Kowalski J, Donnellan W, The A, Reddy V, Jaye DL, Foran J. Examining racial differences in diffuse large B-cell lymphoma presentation and survival. Leuk Lymphoma. 2013 Feb; 54(2):268-76.
    View PubMed
  28. Foran JM, Shammo JM. Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes. Am J Med. 2012 Jul; 125(7 Suppl):S6-13.
    View PubMed
  29. Foran JM. Gemtuzumab: time to bring back on the market? Clin Adv Hematol Oncol. 2012 May; 10: (5)326-7.
    View PubMed
  30. Foran JM. Targeted therapy of acute myeloid leukemia in 2012: towards individualized therapy. Hematology. 2012 Apr; 17 Suppl 1:S137-40.
    View PubMed
  31. Jiang L, Li Z, Finn LE, Personnet DA, Edenfield B, Foran JM, Jaeckle KA, Reimer R, Menke DM, Ketterling RP, Tun HW. Primary central nervous system B cell lymphoma with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma. Int J Clin Exp Pathol. 2012; 5(1):72-6. Epub 2012 Jan 01.
    View PubMed
  32. Vaklavas C, Steciuk MR, Ren Y, Baird MF, Mikhail FM, Foran JM. A case of acute promyelocytic leukemia without RARalpha rearrangement and apparently normal cytogenetics. Clin Lymphoma Myeloma Leuk. 2011 Dec; 11(6):521-4. Epub 2011 May 19.
    View PubMed
  33. O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, Foran JM, Goorha S, Maness LJ, Marcucci G, Maslak P, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, National Comprehensive Cancer Network. Acute myeloid leukemia. J Natl Compr Canc Netw. 2011 Mar; 9(3):280-317.
    View PubMed
  34. Shammo JM, Foran JM, Houk A, Epstein J, Narang M, Rubinstein P, Dennison B, Latsko JM, Naganna G. An examination of educational gaps in the diagnosis and treatment of myelodysplastic syndromes. Cancer Control. 2011 Jan; 18(1):65-74.
    View PubMed
  35. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P, National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw. 2011 Jan; 9(1):30-56.
    View PubMed
  36. Pavletic SZ, Kumar S, Mohty M, de Lima, Foran JM, Pasquini M, Zhang MJ, Giralt S, Bishop MR, Weisdorf D. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant. 2010 Jul; 16(7):871-90. Epub 2010 Apr 24.
    View PubMed
  37. Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, Schmidt-Wolf IG, Schuler M, Sierra J, Smith MR, Verhoef G, Winter JN, Boni J, Vandendries E, Shapiro M, Fayad L. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol. 2010 Apr 20; 28(12):2085-93. Epub 2010 Mar 22.
    View PubMed
  38. Foran JM. New prognostic markers in acute myeloid leukemia: perspective from the clinic. Hematology Am Soc Hematol Educ Program. 2010; 2010:47-55.
    View PubMed
  39. Keegan TH, McClure LA, Foran JM, Clarke CA. Improvements in survival after follicular lymphoma by race/ethnicity and socioeconomic status: a population-based study. J Clin Oncol. 2009 Jun 20; 27(18):3044-51 Epub 2009 May 18.
  40. Crawford J, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Goemann M, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, Michaud LB, Miyata SC, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK, National Comprehensive Cancer Network. Myeloid growth factors. J Natl Compr Canc Netw. 2009 Jan; 7(1):64-83.
    View PubMed
  41. O'Donnell MR, Appelbaum FR, Coutre SE, Damon LE, Erba HP, Foran J, Lancet J, Maness LJ, Marcucci G, Maslak PG, Millenson M, Moore JO, Ravandi F, Schuening F, Shami P, Smith BD, Stone RM, Tallman MS, Wang E, White FL. Acute myeloid leukemia. J Natl Compr Canc Netw. 2008 Nov; 6(10):962-93.
    View PubMed
  42. Greenberg PL, Attar E, Battiwalla M, Bennett JM, Bloomfield CD, DeCastro CM, Deeg HJ, Erba HP, Foran JM, Garcia-Manero G, Gore SD, Head D, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Saba HI, Shami PJ, Spiers K, Stone RM, Tallman MS, Westervelt P, NCCN Myelodysplastic Syndromes Panel. Myelodysplastic syndromes. J Natl Compr Canc Netw. 2008 Oct; 6(9):902-26.
    View PubMed
  43. Kruspe RC, Ashraf KK, Foran JM, Salzman DE, Reddy VV, Vaughan WP. Successful treatment of T-cell prolymphocytic leukemia with full-intensity conditioning followed by matched unrelated donor allogeneic stem cell transplantation. Clin Adv Hematol Oncol. 2007 Nov; 5(11):882-4; discussion 884.
    View PubMed
  44. Hilliard NJ, Warraich IA, Kruspe R, Hyche B, Foran J, Reddy VB. Idiopathic eosinophilia associated CMML-2 with overexpression of the ETV6 gene. Lab Med. 2007 Feb; 38(2):100-2.
  45. O'Donnell MR, Appelbaum FR, Baer MR, Byrd JC, Coutre SE, Damon LE, Erba HP, Estey E, Foran J, Lancet J, Maness LJ, Maslak PG, Millenson M, Moore JO, Przepiorka D, Shami P, Smith BD, Stone RM, Tallman MS. Acute myeloid leukemia clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jan; 4(1):16-36.
    View PubMed
  46. Aoun P, Wiggins M, Pickering D, Foran J, Rasheed H, Pavletic SZ, Sanger W. Interphase fluorescence in situ hybridization studies for the detection of 9q34 deletions in chronic myelogenous leukemia: a practical approach to clinical diagnosis. Cancer Genet Cytogenet. 2004 Oct 15; 154(2):138-43.
    View PubMed
  47. O'Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA, Yuen HA, Louie SG, Kim H, Nicholas S, Heinrich MC, Berdel WE, Bello C, Jacobs M, Scigalla P, Manning WC, Kelsey S, Cherrington JM. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res. 2003 Nov 15; 9(15):5465-76.
    View PubMed
  48. Pavletic SZ, Bociek RG, Foran JM, Rubocki RJ, Kuszynski CA, Wisecarver JL, Hatcher L, Lucas DM, Byrd JC, Grever MR, Joshi SS, Hardiman P, Smith LM, McGuire TR, Bierman PJ, Vose JM, Armitage JO, Talmadge JE. Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation. Transplantation. 2003 Sep 15; 76(5):877-81.
    View PubMed
  49. Hough RE, Lorigan PC, Poynton C, Newland A, Gupta RK, Foran J, Hancock BW. A phase II protection study of BB-10010 in patients with high grade non-Hodgkin's lymphoma undergoing intensive chemotherapy. Int J Oncol. 2003 Feb; 22(2):421-4.
    View PubMed
  50. Joshi SS, Bishop MR, Lynch JC, Tarantolo SR, Abhyankar S, Bierman PJ, Vose JM, Geller RB, McGuirk J, Foran J, Bociek RG, Hadi A, Day SD, Armitage JO, Kessinger A, Pavletic ZS. Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study. Cytotherapy. 2003; 5(6):542-52.
    View PubMed
  51. Foran JM. Antibody-based therapy of non-Hodgkin's lymphoma. Best Pract Res Clin Haematol. 2002 Sep; 15(3):449-65.
    View PubMed
  52. Foran JM, Norton AJ, Micallef IN, Taussig DC, Amess JA, Rohatiner AZ, Lister TA. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br J Haematol. 2001 Sep; 114(4):881-3.
    View PubMed
  53. Edwards MJ, Walker R, Vinnicombe S, Barlow C, MacCallum P, Foran JM. Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma. Ann Oncol. 2001 Sep; 12(9):1327-9.
    View PubMed
  54. Silberstein L, Davies A, Kelsey S, Foran J, Murrell C, D'Cruz D, Vinnicombe S, Norton A, Cavenagh J. Myositis, polyserositis with a large pericardial effusion and constrictive pericarditis as manifestations of chronic graft-versus-host disease after non-myeloablative peripheral stem cell transplantation and subsequent donor lymphocyte infusion. Bone Marrow Transplant. 2001 Jan; 27(2):231-3.
    View PubMed
  55. Crawley CR, Foran JM, Gupta RK, Rohatiner AZ, Summers K, Matthews J, Micallef IN, Radford JA, Johnson SA, Johnson PW, Sweetenham JW, Lister TA. A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. Ann Oncol. 2000 Jul; 11(7):861-5.
    View PubMed
  56. Shamash J, Walewski J, Apostolidis J, Wilson AM, Foran JM, Gupta RK, Rohatiner AZ, Kelsey SM, Lister TA. Low-dose continuous chemotherapy (LBCMVD-56) for refractory and relapsing lymphoma. Ann Oncol. 2000 Jul; 11(7):857-60.
    View PubMed
  57. Foran JM, Gupta RK, Cunningham D, Popescu RA, Goldstone AH, Sweetenham JW, Pettengell R, Johnson PW, Bessell E, Hancock B, Summers K, Hughes J, Rohatiner AZ, Lister TA. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol. 2000 Apr; 109(1):81-8.
    View PubMed
  58. Micallef IN, Lillington DM, Apostolidis J, Amess JA, Neat M, Matthews J, Clark T, Foran JM, Salam A, Lister TA, Rohatiner AZ. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol. 2000 Mar; 18(5):947-55.
    View PubMed
  59. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A, Lister TA. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000 Jan; 18(2):317-24.
    View PubMed
  60. Foran JM, Cunningham D, Coiffier B, Solal-Celigny P, Reyes F, Ghielmini M, Johnson PW, Gisselbrecht C, Bradburn M, Matthews J, Lister TA. Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol. 2000; 11 Suppl 1:117-21.
    View PubMed
  61. Micallef IN, Apostolidis J, Rohatiner AZ, Wiggins C, Crawley CR, Foran JM, Leonhardt M, Bradburn M, Okukenu E, Salam A, Matthews J, Cavenagh JD, Gupta RK, Lister TA. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J. 2000; 1(6):367-73.
    View PubMed
  62. Foran JM, Slater SE, Norton AJ, Wilkes SJ, Hart IJ, Rohatiner AZ. Monoclonal Epstein-Barr virus-related lymphoproliferative disorder following adult acute lymphoblastic leukaemia. Br J Haematol. 1999 Sep; 106(3):713-6.
    View PubMed
  63. Papamichael D, Norton AJ, Foran JM, Mulatero C, Mathews J, Amess JA, Bradburn M, Lister TA, Rohatiner AZ. Immunocytoma: a retrospective analysis from St Bartholomew's Hospital-1972 to 1996. J Clin Oncol. 1999 Sep; 17(9):2847-53.
    View PubMed
  64. Baldini EH, Demetri GD, Fletcher CD, Foran J, Marcus KC, Singer S. Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome. Ann Surg. 1999 Jul; 230(1):79-86.
    View PubMed
  65. Foran JM, Oscier D, Orchard J, Johnson SA, Tighe M, Cullen MH, de Takats PG, Kraus C, Klein M, Lister TA. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. J Clin Oncol. 1999 May; 17(5):1574-9.
    View PubMed
  66. Foran JM, Rohatiner AZ, Coiffier B, Barbui T, Johnson SA, Hiddemann W, Radford JA, Norton AJ, Tollerfield SM, Wilson MP, Lister TA. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol. 1999 Feb; 17(2):546-53.
    View PubMed
  67. Apostolidis J, Foran JM, Johnson PW, Norton A, Amess J, Matthews J, Bradburn M, Lister TA, Rohatiner AZ. Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol. 1999 Jan; 17(1):216-21.
    View PubMed
  68. Foran JM, Apostolidis J, Papamichael D, Norton AJ, Matthews J, Amess JA, Lister TA, Rohatiner AZ. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Ann Oncol. 1998 Aug; 9(8):865-9.
    View PubMed